secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001326732-25-000002
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor: $707M cash; XmAb541 selectivity; plamotamab B-cell depletion; XmAb808 dose escalation; vudalimab enrollment done
--------------------------------------------------------------------------------

- Preliminary cash & marketable securities ~$707M at Dec 31, 2024, up from $697M in 2023; expected to fund ops into 2028.
- New preclinical data shows XmAb541 (CLDN6 x CD3) selective binding to CLDN6 over CLDN9.
- Plamotamab (CD20 x CD3) Phase 1 data shows deep peripheral B-cell depletion in lymphoma patients.
- XmAb808 (B7-H3 x CD28) has resumed dose escalation in clinical study.
- Enrollment completed in three ongoing vudalimab (PD-1 x CTLA-4) studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000002/0001326732-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000002/xncr-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001326732-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer